Sugi Predict

Sugi Predict / Compounds / SCHEMBL239407

SCHEMBL239407

SCHEMBL239407

COC(=O)NC(C(=O)N1CCCC1C(=O)O)C(C)C

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ACE P12821 6/20 0.52
▸ REN P00797 4/20 0.52
▸ KDM4E B2RXH2 1/20 0.52
▸ F2 P00734 1/20 0.52
▸ LMNA P02545 1/20 0.52
▸ LTA4H P09960 1/20 0.52
▸ MAPT P10636 1/20 0.52
▸ PEPD P12955 1/20 0.52
▸ ALOX15 P16050 1/20 0.52
▸ PTGS1 P23219 1/20 0.52
▸ HTR2A P28223 1/20 0.52
▸ PTGS2 P35354 1/20 0.52
▸ HRH1 P35367 1/20 0.52
▸ THPO P40225 1/20 0.52
▸ PMP22 Q01453 1/20 0.52
▸ HSD17B10 Q99714 1/20 0.52
▸ ACE2 Q9BYF1 1/20 0.52
▸ NR1I2 O75469 1/20 0.49
▸ ABCB11 O95342 1/20 0.49
▸ CYP3A4 P08684 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL239406 1.00 ACE (0.52) ACERENKDM4EF2LMNA
SCHEMBL242197 1.00 ACE (0.52) ACERENKDM4EF2LMNA
SCHEMBL12598148 1.00 ACE (0.52) ACERENKDM4EF2LMNA
SCHEMBL12567110 1.00 ACE (0.52) ACERENKDM4EF2LMNA
SCHEMBL15692916 0.96 ACE (0.48) ACERENKDM4EF2LMNA
SCHEMBL21641824 0.89 ACE (0.50) ACERENKDM4EF2LMNA
SCHEMBL21641823 0.89 ACE (0.50) ACERENKDM4EF2LMNA
SCHEMBL18913820 0.89 ACE (0.50) ACERENKDM4EF2LMNA
SCHEMBL12566960 0.89 DPP4 (0.51) NR1I2ABCB11CYP3A4CYP2C9OPRK1
SCHEMBL12599485 0.89 CYP3A4 (0.49) PEPDNR1I2ABCB11CYP3A4CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230285378-A1 Anti-Viral Compounds ABBVIE INC. (US) 2023-09-14 — — US disclosed
US-20210053981-A1 ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. 2021-02-25 — — US disclosed
EP-3778606-A2 CONDENSED IMIDAZOLYLIMIDAZOLES AS ANTIVIRAL COMPOUNDS Gilead Pharmasset LLC (US) 2021-02-17 — — EP disclosed
WO-2020219808-A1 DICARBAMATE INHIBITORS OF NS5A FOR TREATMENT OF HEPATITIS C VIRUS INFECTIONS AND RELATED DISEASES BETA PHARMA, INC. (US) 2020-10-29 — — WO disclosed
US-10807990-B2 Antiviral compounds GILEAD PHARMASSET LLC (US) 2020-10-20 — — US disclosed
US-10800789-B2 Antiviral compounds GILEAD PHARMASSET LLC (US) 2020-10-13 — — US disclosed
EP-3699176-A2 ANTIVIRAL COMPOUNDS Gilead Pharmasset LLC (US) 2020-08-26 — — EP disclosed
US-20200123132-A1 ANTIVIRAL COMPOUNDS GILEAD PHARMASSET LLC 2020-04-23 — — US disclosed
US-20200071337-A1 ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. 2020-03-05 — — US disclosed
US-20190337960-A1 ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. 2019-11-07 — — US disclosed
EP-2455376-A1 Heterocyclic compounds as inhibitors of hepatitis C virus (HCV) Abbott Laboratories (US) 2012-05-23 — — EP disclosed
WO-2012051361-A1 ANTI-VIRAL COMPOUNDS ABBOTT LABORATORIES (US) 2012-04-19 — — WO disclosed
US-20120039847-A1 Hepatitis C Virus Inhibitors ZHAO SHU-HAI (CN) 2012-02-16 — — US disclosed
US-20120004196-A1 Anti-Viral Compounds Abbott Labaoratories (US) 2012-01-05 — — US disclosed
EP-2368890-A1 Hepatitis C virus inhibitors Abbott Laboratories (US) 2011-09-28 — — EP disclosed
US-20110207699-A1 Anti-Viral Compounds Abbott Labaoratories (US) 2011-08-25 — — US disclosed
EP-2337781-A2 ANTI-VIRAL COMPOUNDS TO TREAT HCV INFECTION Abbott Laboratories (US) 2011-06-29 — — EP disclosed
US-20110092415-A1 Anti-Viral Compounds Abbott Labaoratories (US) 2011-04-21 — — US disclosed
US-20100317568-A1 Anti-Viral Compounds Abbott Labaoratories (US) 2010-12-16 — — US disclosed
WO-2010144646-A2 ANTI-VIRAL COMPOUNDS ABBOTT LABORATORIES (US) 2010-12-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100317568-A1 Anti-Viral Compounds HAVCR2, EIF2AK2, MAVS ACE 256/4885REN 2184/4885KDM4E 2318/4885
US-20200071337-A1 ANTIVIRAL COMPOUNDS MAVS, EIF2AK2, SARS1 ACE 133/4885REN 3159/4885KDM4E 3215/4885
US-20230285378-A1 Anti-Viral Compounds HAVCR2, EIF2AK2, MAVS ACE 256/4885REN 2184/4885KDM4E 2318/4885
US-20120039847-A1 Hepatitis C Virus Inhibitors HAVCR2, HCCS, LIPC ACE 174/4885REN 3293/4885KDM4E 3304/4885
US-20110092415-A1 Anti-Viral Compounds HAVCR2, EIF2AK2, MAVS ACE 256/4885REN 2184/4885KDM4E 2318/4885
US-10807990-B2 Antiviral compounds MAVS, EIF2AK2, SARS1 ACE 133/4885REN 3159/4885KDM4E 3215/4885
US-20110207699-A1 Anti-Viral Compounds HAVCR2, EIF2AK2, MAVS ACE 256/4885REN 2184/4885KDM4E 2318/4885
US-20200123132-A1 ANTIVIRAL COMPOUNDS MAVS, EIF2AK2, ZC3HAV1 ACE 44/4885REN 1688/4885KDM4E 2496/4885
US-10800789-B2 Antiviral compounds MAVS, EIF2AK2, SARS1 ACE 133/4885REN 3159/4885KDM4E 3215/4885
US-20120004196-A1 Anti-Viral Compounds HAVCR2, EIF2AK2, MAVS ACE 256/4885REN 2184/4885KDM4E 2318/4885
US-20210053981-A1 ANTIVIRAL COMPOUNDS MAVS, EIF2AK2, SARS1 ACE 133/4885REN 3159/4885KDM4E 3215/4885
US-20190337960-A1 ANTIVIRAL COMPOUNDS MAVS, EIF2AK2, SARS1 ACE 133/4885REN 3159/4885KDM4E 3215/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.